Building Medical Affairs Teams of The Future: A Strategic Advantage in the Age of Data Driven Health

October 14, 2020 8:00 AM - 9:00 AM

Webinar, click "live-stream" button to view

Add to Calendar 10/14/2020 8:00:16 AM 10/14/2020 9:00:16 AM Building Medical Affairs Teams of The Future: A Strategic Advantage in the Age of Data Driven Health

Medical Affairs was created as a support function to marketing and sales but has evolved over the last decade into the third pillar of pharmaceutical and biotechnology companies. Today, with the breadth and depth of diverse data sources, rapid changes in technology, increasing scientific complexity of treatments, and regulatory and economic trends, organizations that cultivate strategic and diversely talented medical teams have the competitive advantage.

Forward looking organizations are building the medical affairs teams of the future. These teams are breaking down traditional silos and developing capacities to evolve data generation across clinical development, HEOR and real-world evidence. They are evolving to effectively translate, not only the clinical, but also the economic impact to increasingly important stakeholders, especially payer decision-makers with unprecedented size and scale and knowledge-empowered patients.

In a day of rapid scientific and medical advancement, equity, and economic concerns, the pharmaceutical industry requires strategic medical leadership. Required are highly skilled and empowered medical affairs teams that harness data and insights to help physicians, payers, and patients choose the right medication, at the right time, to drive meaningful impact for individual patients and societal health outcomes.

Join us for an overview from McKinsey of how medical affairs has evolved over time and where it is headed followed by a panel discussion on how life sciences companies of all sizes can best hire, develop, and leverage these skilled professionals for a competitive advantage.

Sponsored by the MassBio MarCom and Commercial Forum Working Group.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
 

Webinar, click "live-stream" button to view

Medical Affairs was created as a support function to marketing and sales but has evolved over the last decade into the third pillar of pharmaceutical and biotechnology companies. Today, with the breadth and depth of diverse data sources, rapid changes in technology, increasing scientific complexity of treatments, and regulatory and economic trends, organizations that cultivate strategic and diversely talented medical teams have the competitive advantage.

Forward looking organizations are building the medical affairs teams of the future. These teams are breaking down traditional silos and developing capacities to evolve data generation across clinical development, HEOR and real-world evidence. They are evolving to effectively translate, not only the clinical, but also the economic impact to increasingly important stakeholders, especially payer decision-makers with unprecedented size and scale and knowledge-empowered patients.

In a day of rapid scientific and medical advancement, equity, and economic concerns, the pharmaceutical industry requires strategic medical leadership. Required are highly skilled and empowered medical affairs teams that harness data and insights to help physicians, payers, and patients choose the right medication, at the right time, to drive meaningful impact for individual patients and societal health outcomes.

Join us for an overview from McKinsey of how medical affairs has evolved over time and where it is headed followed by a panel discussion on how life sciences companies of all sizes can best hire, develop, and leverage these skilled professionals for a competitive advantage.

Sponsored by the MassBio MarCom and Commercial Forum Working Group.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
 

MD, Vice President, U.S. and LATAM Medical Affairs, Alnylam Pharmaceuticals
Laura is Vice President, U.S. & LATAM Medical Affairs at Alnylam, where she is responsible for leading the U.S. and LATAM Medical Affairs organization across all therapeutic areas. During her tenure at Alnylam, she has supported the launches of ONPATTRO, GIVLAARI and lumasiran. Prior to joining Alnylam, Laura spent 14 years at Sanofi Genzyme where she was most recently Vice President, Head of Multiple Sclerosis Medical Affairs in North America. Earlier at Sanofi, she led the US LEMTRADA Medical Directors team and established the Multiple Sclerosis global scientific communications group. In these roles, she helped launch two therapies for multiple sclerosis, AUBAGIO and LEMTRADA. Prior to her tenure in medical affairs, Laura worked in oncology business development, program management, strategy as well as marketing in roles of increasing responsibility. Laura holds an AB from Harvard College, an MD from Harvard Medical School and an MBA from MIT’s Sloan School of Management. She trained for two years as an OB-GYN at the Brigham and Women’s Hospital and Massachusetts General Hospital. When not working, Laura enjoys spending time with family and friends, reading, skiing, traveling and playing tennis. Laura serves on the board of trustees for Vincent Memorial Hospital, The Boston Home and the Massachusetts Eye and Ear Infirmary. She lives in Newton with her husband and three daughters.